
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc has demonstrated robust growth metrics, particularly with the significant increase in Chromium reaction volumes, indicating resilience in demand despite ongoing pricing pressures in the pharmaceutical sector. The company's consumables segment is projected to experience substantial growth, with expectations of a 5-19x increase by platform by 2027, highlighting strong revenue potential. Additionally, the integration of their diverse product offerings supports the company's strategic position in the life sciences technology market, aligning with the complexities of biological research and analysis.
Bears say
10x Genomics has experienced a contraction in revenues during 2024, attributed to double-digit pricing pressure and flat to modestly lower volumes, with growth not anticipated to accelerate until 2027. The company reported weaker-than-expected Q4 results, including an earnings per share miss and a full-year revenue outlook that fell below market expectations. Additionally, despite some expansion in company segments since 2021, they have not met the high expectations set by analysts, contributing to a decline of over 90% in the stock price since its peak.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares